AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
Condition(s):FrailtyLast Updated:July 14, 2021Completed
Hide Studies Not Open or Pending
Condition(s):FrailtyLast Updated:July 14, 2021Completed
Condition(s):Obstetric Labour, PrematureLast Updated:July 28, 2020Terminated
Condition(s):Subarachnoid Hemorrhage; HypertensionLast Updated:March 2, 2023Terminated
Condition(s):Osteoporosis, PostmenopausalLast Updated:May 23, 2017Unknown status
Condition(s):Osteogenesis Imperfecta; Osteogenesis Imperfecta Type IIILast Updated:February 28, 2024Not yet recruiting
Condition(s):Breast Cancer; OsteoporosisLast Updated:July 19, 2016Completed
Condition(s):Hepatocellular CarcinomaLast Updated:December 22, 2021Not yet recruiting
Condition(s):Chronic Myeloproliferative Disorders; Infection; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Adult Solid Tumor, Protocol SpecificLast Updated:February 15, 2013Withdrawn
Condition(s):Post-Traumatic HeadacheLast Updated:September 2, 2022Recruiting
Condition(s):Liver FailureLast Updated:January 3, 2019Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.